摘要
目的:探讨ICSs布地奈德治疗稳定期慢性阻塞性肺疾病(COPD)的临床疗效。方法:回顾性分析86例稳定期COPD患者的临床资料,将86例患者随机分为观察组44例和对照组42例,对照组给予常规治疗,观察组在常规治疗的基础上加用ICSs布地奈德治疗。结果:观察组急性加重住院人次明显少于对照组,差异有统计学意义(P<0.05);两组治疗后各观察指标均较之治疗前改善(P<0.05),但观察组改善程度均优于对照组,两组比较差异均有统计学意义(P<0.05)。结论:ICSs治疗稳定期COPD疗效显著,能够有效延缓肺功能衰退,改善症状和使患者病情急性加重的次数减少,值得临床推广。
Objective:To probe into the clinical effect of ICSs budesonide on stabilized patients with chronic pulmonary disease.Method: Clinical data of 86 stabilized patients with COPD were analyzed retrospectively.86 cases were divided into observation group(44 cases)and control group (42 cases).The control group were given routine treatment.ICSs budesonide was added to treat patients of observation group,on the basis of routine treatment.Result:The number of inpatients resulting from acute exacerbation in observation group was obviously less than that of control group,two groups compared with a statistically significant difference(P &lt;0.05);all observational indices of two groups after treatment were better than those before treatment(P &lt;0.05).However,the improved degree of observation group was better than that of control group.The differences between two groups had a statistically significant(P &lt;0.05).Conclusion:ICSs has significant effect on stabilized patients with COPD.It can effectively slow the decline in lung function and improve symptoms to reduce the number of patients with acute exacerbation.Therefore,it is worthy of clinical promotion.
出处
《中国医学创新》
CAS
2013年第19期46-48,共3页
Medical Innovation of China